Loading...
XNAS
HSDT
Market cap98mUSD
Jul 09, Last price  
1.83USD
1D
8.93%
1Q
-3.17%
Jan 2017
-100.00%
IPO
-100.00%
Name

Helius Medical Technologies Inc

Chart & Performance

D1W1MN
XNAS:HSDT chart
P/E
P/S
17.76
EPS
Div Yield, %
Shrs. gr., 5y
240.87%
Rev. gr., 5y
55.54%
Revenues
6m
+1,057.12%
000000478,0001,496,000661,000522,000787,000644,000520,0006,017,000
Net income
-41m
L+248.24%
-8,517,850-1,067,284-9,838,317-6,881,812-12,040,000-28,024,000-28,623,000-9,781,000-14,130,000-18,132,000-14,072,000-8,850,000-11,742,000-40,890,000
CFO
-17m
L+49.57%
-12,014-348,698-6,321,285-7,937,412-7,885,000-19,325,000-19,621,000-20,999,000-11,738,000-13,388,000-14,310,000-10,416,000-11,041,000-16,514,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Helius Medical Technologies, Inc. operates as a neurotechnology firm, dedicated to conceiving, licensing, and incorporating non-invasive technologies. These innovations aim to alleviate symptoms stemming from neurological disorders or injuries. Its flagship product is the Portable Neuromodulation Stimulator (PoNS), a medical apparatus sanctioned for use in Canada to address chronic balance impairments associated with mild-to-moderate traumatic brain injury. The PoNS system functions by stimulating cranial nerves via the tongue, with the goal of rehabilitating compromised bodily functions. The company's main offices are located in Newtown, Pennsylvania.
IPO date
Jun 27, 2014
Employees
19
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT